Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
8 search results for:

Blinatumomab 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 09-04-2018 | FDA | News | Article
    approvalsWatch

    FDA announces further approvals for nilotinib, blinatumomab

    The decision follows the phase II BLAST trial , in which undetectable minimal residual disease was achieved by 85% of 52 participants in first complete remission and by 72% of 18 in second complete remission after one cycle of blinatumomab therapy.

  2.
    16-02-2017 | Image

    Table 2: Clinical efficacy of blinatumomab
  3. 14-03-2018 | Article

    Advisory board comment

    Rituximab has already been given to ALL patients with CD20-positive expression, and the sequential addition of immunotherapy with bispecific monoclonal antibodies such as blinatumomab may also be effective means of eliminating minimal residual disease with a potentially acceptable toxicity in older patients [12], although large-scale efficacy data are lacking.

    Author:
    Xavier Thomas MD
  4. 22-07-2017 | Lymphoma | Article

    An update on the use of immunotherapy in the treatment of lymphoma

    This review by Marron et al. covers promising data on advances in antibody-based therapies, immunomodulators and checkpoint-blocking therapies in the treatment of lymphomas. Marron TU, Kalac M, Brody J. Curr Hematol Malig Rep 2017. doi:10.1007/s11899-017-0396-8

  5. 29-12-2016 | Lymphoma | Article

    The landscape of new drugs in lymphoma

    A higher dose of blinatumomab is needed in these patients than for the treatment of those with ALL.

    Author:
    Anas Younes, Stephen Ansell, Nathan Fowler, Wyndham Wilson, Sven de Vos, John Seymour, Ranjana Advani, Andres Forero, Frank Morschhauser, Marie Jose Kersten, Kensei Tobinai, Pier Luigi Zinzani, Emanuele Zucca, Jeremy Abramson, Julie Vose
  6. 15-11-2016 | Acute lymphoblastic leukemia | Book chapter | Article

    Therapeutic management of acute lymphoblastic leukemia

    The CD19 BiTE antibody blinatumomab is composed of CD19- and CD3-binding portions and links T cells to CD19+ ALL cells.

    Author:
    Karsten Spiekermann
  7. 26-01-2017 | Hematologic cancers | Editorial | Article

    Immunotherapy comes of age in blood cancers

    Blinatumomab has two antibody-biding sites, a CD3 site for T cells, and a CD19 site for the malignant B cells.

    Author:
    Jasmine Zain MD
  8. 03-11-2015 | Hematologic cancers | Article

    Novel immunotherapies in lymphoid malignancies

    Transient B-cell aplasia and resulting hypogammaglobulinaemia have been reported in patients treated with blinatumomab. 110 Predictive markers of neurological adverse events of blinatumomab have been explored.

    Author:
    Connie Lee Batlevi, Eri Matsuki, Renier J. Brentjens, Anas Younes
  • 1

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.